Synergy between Synthetic Long Peptides (SLP®) immunotherapeutics and standard chemotherapy in late stage cancer including meaningful survival improvements in SLP immune responders
Leiden, The Netherlands, 19 March 2020 — ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, announces publication of its phase 2, CervISA study in the peer-reviewed journal “Science Translational Medicine”. The paper titled ‘Strong vaccine responses during chemotherapy are associated with prolonged survival’ can be found here.
The CervISA study was an open label, phase 2 study in patients with late stage HPV16 positive cervical cancer. Seventy-seven patients were treated with ISA Pharma’s lead product, ISA101b, an HPV16-specific immunotherapeutic
to boost late-stage development of novel therapy to treat life-threatening, virus-induced
by the “InnovFin
EU-finance for innovators”
The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA’s therapy for cancers caused by the Human Papillomavirus type 16 (HPV16).
HPV16 infection can cause cervical, head & neck and anogenital cancers.
These cancers can be severe and life-threatening, with low overall survival
rates of advanced stages. Cervical cancer is the 2nd most common
cancer in women aged 15 to 44 years in Europe, with HPV16 causing over 35,000
new cases and 15,000 deaths each year. The
– Seasoned biotech expert to support corporate development
Leiden, The Netherlands, September 02, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the addition of Dr. Markwin Velders to its Supervisory Board. Dr. Velders brings many years of experience in the biotech industry and currently holds a position as VP Operations and Managing Director at Kite Pharma EU, a leading company in the field of immuno-oncology and cell therapy.
“As we are entering the final stages of clinical development for our lead product ISA101b, we are happy to further